贝伐珠单抗联合紫杉醇+顺铂对晚期子宫颈癌 患者血清肿瘤标志物、miR-367、miR-383的 影响

打开文本图片集

Effectsof Bevacizumab Combined with Paclitaxel and Cisplatin on Serum Tumor Markers，miR-367 and miR-383 in Patients with Advanced Cervical Cancer/ZENG Yuhui，LIU Shuaiting，JIANG Meijiao， HUANG Xiaojuan.//Medical Innovation of China，2025，22（30）： 055-059

[Abstract]Objective：To investigate the effctsofthecombinationofBevacizumab，Paclitaxel，andCisplatin on serum tumor markers， microRNA-367 （miR-367），and microRNA-383 （miR-383） in patients with advanced cervical cancer.Method：According to the random numbertable method，9O patients with advanced cervical cancer from Gynaecology Department， Ganzhou Women and Children's Health Care Hospital from August 2023 to June 2O24 were divided into control group （only receiving Paclitaxel + Cisplatin chemotherapy，45 cases） and observation group （receiving the combination of Bevacizumab，Paclitaxel，and Cisplatin chemotherapy，45cases）. The effcacy，serum tumor markers，miR-367 and miR-383 levels before and after treatment，and adverse reactions were compared between the two groups.Result： Three months after the end of the treatment， observation group showed higher objective response rate than thatof control group，with statisticallysignificant difference （ P <0.05）; there was no statistically significant difference in the disease control rate between the two groups （ P >0.05）.After treatment，squamous cellcarcinoma antigen （SCCA），carcinoembryonic antigen （CEA），and carbohydrateantigen 125 （CA125）in both groups decreased，and those in the observation group were lower than those in the control group （ P <0.05）; miR-367and miR-383 relative expression increased，and those inthe observation group were higher than those in the control group，with statistically significant differences （ P <0.05）.There was no statistically significant difference in the incidence of adverse reactions between the two groups （ P >0.05）. Conclusion： The combination of Bevacizumab，Paclitaxel，and Cisplatin can reduce the levels of serum tumor markers，regulate the expression of miR-367and miR-383，and improve the treatment effect in patients with advanced cervical cancer.

[Keywords]Cervical cancer Bevacizumab Paclitaxel Cisplatin Tumor markerMicroRNA

First-author's address： Gynaecology Department， Ganzhou Women and Children's Health Care [ospital，Ganzhou 34100o， China

doi：10.3969/j.issn.1674-4985.2025.30.014

晚期子宫颈癌因癌细胞多已侵犯周围组织或远处转移，病情复杂且扩散范围广泛，常规治疗手段难以有效控制，治疗难度显著增加，患者整体预后不佳[。（剩余6885字）